Clinical Outcomes in Continuous Clinical Responders with Moderately to Severely Active Ulcerative Colitis: Subanalyses from the PURSUIT-SC Maintenance Study
William J. Sandborn(University of San Diego), Paul Rutgeerts(KU Leuven), Walter Reinisch(Medical University of Vienna), Dino Tarabar(Military Medical Academy), Peter G. Gibson(University Gastroenterology), Brian G. Feagan(Western University), Colleen Marano(Johnson & Johnson (United States)), Jean–Frédéric Colombel(Icahn School of Medicine at Mount Sinai), Ruji Yao(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jewel Johanns(Johnson & Johnson (United States)), Richard Strauß(Hennepin County Medical Center), Hongyan Zhang(Northwest A&F University), Zbigniew Hebzda(1 Military Clinical Hospital with Outpatient Clinic)
Cited by 2
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k